Reimbursed Care Access in Guyana

Currently classified as a strictly controlled substance under Guyana’s Narcotic Drugs and Psychotropic Substances (Control) Act and related amendments, with no authorized medical use outside of approved clinical research. # #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances laws, with no authorized medical use outside of approved clinical research. Possession and trafficking are criminal offences under the national control regime. # #

There is no publicly available record of a national marketing authorisation or a public reimbursement pathway for esketamine (SPRAVATO®) in Guyana; access would therefore be limited to imported product used under special import/compassionate/clinical‑trial arrangements or administered at private facilities with appropriate regulatory permissions. Guyana’s national narcotics/psychotropic framework governs controlled substances and recent amendments explicitly extended control to synthetic/nonnatural psychotropic drugs, which increases regulatory scrutiny on novel agents. For context about esketamine regulatory frameworks elsewhere and REMS/REMS‑like supervised administration models, see SPRAVATO® regulatory information. # #

Ketamine is a licensed anesthetic and analgesic regularly used within medical settings worldwide and is included on the WHO Model List of Essential Medicines for anesthesia/analgesia; as such, its use for standard medical indications (e.g., anesthesia, emergency analgesia) is permitted in Guyanese hospitals and clinics subject to normal pharmaceutical and hospital governance. The Guyanese regulatory and enforcement framework has, however, been amended to criminalize non‑medical/illicit use of synthetic psychotropic substances including ketamine when used outside authorized medical contexts, indicating a strict separation between legitimate clinical use and illicit consumption. Public reimbursement for novel psychiatric indications (e.g., ketamine infusions for depression) is not documented in national Ministry of Health published financial‑assistance guidelines and, if available, would likely be handled case‑by‑case through private providers or the Ministry’s medical assistance processes rather than an established, routine public benefit. See the national drugs control documentation and Guyana Ministry of Health medical treatment assistance guidance for financial aid processes. # # #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances legislation, with no authorized medical use outside of approved clinical research. Local guidance and summaries list N,N‑DMT among controlled tryptamines; indigenous or sacramental claims (e.g., ayahuasca) are not codified as legal exemptions in national law. # #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances laws (tryptamine class coverage and synthetic psychotropic amendments apply), with no authorized medical use outside of approved clinical research. Although some national lists specifically name N,N‑DMT, the country’s amendments expanding control to synthetic/new psychoactive substances mean 5‑MeO‑DMT is effectively controlled. # #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances legislation, with no authorized medical use outside of approved clinical research. There is no publicly available regulatory framework permitting ibogaine‑assisted treatment in Guyana. #

Ayahuasca contains DMT (a controlled substance); under Guyanese law the presence of DMT in a brew is not exempted and ayahuasca use/possession is therefore unauthorized outside approved research or explicit regulatory permission. Currently classified as a strictly controlled substance context with no sanctioned public‑health or reimbursement pathway. # #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline and related cacti are encompassed by the controlled substances framework. #

Currently classified as a strictly controlled substance under Guyana’s narcotics and psychotropic substances legislation and subsequent amendments that targeted designer and synthetic psychoactive substances; there is no authorized medical use outside of approved clinical research. # #